Genix Pharmaceuticals Corporation (TSXV:GENX)

Market Cap	1.22M -87.8%
Revenue (ttm)	68.00 -98.3%
Net Income	-88.76K
EPS	-0.00
Shares Out	61.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	139,246
Open	0.0200
Previous Close	n/a
Day's Range	0.0200 - 0.0200
52-Week Range	0.0200 - 0.0550
Beta	0.49
RSI	40.48
Earnings Date	Feb 26, 2026

About Genix Pharmaceuticals

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,000
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: GENX

Financial Performance

In fiscal year 2024, Genix Pharmaceuticals's revenue was 4,051, a decrease of -67.19% compared to the previous year's 12,347. Losses were -73,196, -98.33% less than in 2023.